IUGNF Stock Chart & Stats
$0.18
>-$0.01(-3.57%)
At close: 4:00 PM EST
$0.18
>-$0.01(-3.57%)
Day’s Range― - ―
52-Week Range$0.06 - $0.31
Previous CloseN/A
Volume3.00K
Average Volume (3M)16.95K
Market Cap
$32.29M
Enterprise Value$97.38
Total Cash (Recent Filing)$14.14M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Sep 02, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding489,719,850
10 Day Avg. Volume11,247
30 Day Avg. Volume16,948
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$0.17Price Target Upside-2.93% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$1.72M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Capital StructureA debt-to-equity ratio of 0.24 signals limited leverage and lower fixed financing obligations. This conservatism reduces refinancing risk across multi-year clinical programs, preserves flexibility to pursue partnerships or milestone financing, and supports R&D continuity during extended trial cycles.
Diversified Immuno-oncology PipelineMultiple distinct platforms—oncolytic viruses, B-cell activators, CAR T and engagers—spread clinical and scientific risk and create several independent value-inflection points. This breadth aligns with sustained industry interest in cell/immunotherapies and increases the odds of partnering, licensing, or asset-level exits over months.
Positive Free Cash Flow To Net Income RatioA free cash flow to net income ratio of 1.19 indicates free cash flow exceeds accounting losses, suggesting limited capital expenditures and some cash conversion ability. For a development-stage biotech this can modestly extend runway between raises and improve ability to fund incremental trials or partner negotiations.
Bears Say
Severe Revenue DeclineA reported revenue decline of 338.95% demonstrates a collapse in top-line activity and reflects absence of sustainable commercial sales. Such extreme volatility undermines long-term funding visibility, reduces credibility in commercial traction, and heightens dependence on external financing to sustain clinical development.
Persistent Unprofitability And Equity ErosionDeep negative margins and an ROE of -153.27% show current operations destroy shareholder value rather than create it. This persistent unprofitability limits internal reinvestment, weakens negotiating leverage with potential partners, and increases the likelihood of dilutive capital raises to fund ongoing programs.
Weak Operating Cash Generation And Funding RelianceOperating cash flow is negative while the company historically funds R&D via equity placements and rights issues. Reliance on dilutive funding sources raises execution risk if capital markets tighten, increases shareholder dilution over clinical timelines, and can disrupt continuity of multi-stage trials.
Imugene News
IUGNF FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest stock price was $0.06 and its highest was $0.31 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is $32.29M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 41 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -$0.091 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.147.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.03.
How many shares outstanding does Imugene have?
Imugene has 489,719,850 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -$0.091 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in IUGNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.17 (-2.93% Downside)
$0.17 (-2.93% Downside)
Blogger Sentiment
Neutral
IUGNF Sentiment 58%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $56.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IUGNF Stock 12 Month Forecast
Average Price Target
$0.17
▼(-2.93% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Ownership Overview
3.36% Insiders
0.75% Mutual Funds
― Other Institutional Investors
95.89% Public Companies and
Individual Investors